PubMed: Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation

PubMed: Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation

J Nat Prod. 2024 Jun 18. doi: 10.1021/acs.jnatprod.4c00212. Online ahead of print.

ABSTRACT

Despite millennia of therapeutic plant use, deliberate exploitation of Cannabis‘s diverse biomedical potential has only recently gained attention. Bioactivity studies focus mainly on cannabidiol (CBD) and tetrahydrocannabinol (THC) with limited information about the broader cannabinome’s “minor phytocannabinoids”. In this context, our research targeted the synthesis of minor cannabinoids containing a lateral chain with 3 or 4 carbon atoms, focusing on cannabigerol (CBG) and cannabichromene (CBC) analogues. Using known and innovative strategies, we achieved the synthesis of 11 C3 and C4 analogues, five of which were inhibitors of skin inflammation, with the CBG-C4 ester derivative emerging as the most potent compound.

PMID:38889235 | DOI:10.1021/acs.jnatprod.4c00212

https://pubmed.ncbi.nlm.nih.gov/38889235/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Ds1JEbG0OWaBdqM3tTUGjkFhFGaOtMecPdpuvzbuubWi6d9Fn&fc=20231022105433&ff=20240618192324&v=2.18.0.post9+e462414 June 18, 2024 10:00 am